Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Arete Wealth Advisors LLC

Arete Wealth Advisors LLC decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,439 shares of the medical research company’s stock after selling 150 shares during the period. Arete Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $225,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after buying an additional 2,606,950 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after buying an additional 809,605 shares during the period. Fisher Asset Management LLC increased its position in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $39,628,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several recent research reports. Piper Sandler lowered their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. UBS Group lowered their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Barclays boosted their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.65.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $73.32 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a 50-day simple moving average of $69.42 and a 200 day simple moving average of $73.99. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a market cap of $43.24 billion, a PE ratio of 10.58, a P/E/G ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.59 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $2,323,150 in the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.